Compounds > pentachloropseudilin
Page last updated: 2024-12-10

pentachloropseudilin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pentachloropseudilin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3053233
CHEMBL ID1738815
SCHEMBL ID12666317
MeSH IDM0475652

Synonyms (20)

Synonym
a15104 y
2,4-dichloro-6-(3,4,5-trichloro-2-pyrrolyl)phenol
brn 1484123
phenol, 2,4-dichloro-6-(3,4,5-trichloro-2-pyrrolyl)-
2,4-dichloro-6-(3,4,5-trichloro-1h-pyrrol-2-yl)phenol
pentachloropseudilin
bdbm50345503
chembl1738815 ,
2,4-dichloro-6-(3,4,5-trichloro-1h-pyrrol-2yl)phenol
IA2 ,
5-21-03-00330 (beilstein handbook reference)
69640-38-6
2XEL
DTXSID90219907
SCHEMBL12666317
Q27461347
MS-24988
HY-115669
CS-0104318
AKOS040746213

Research Excerpts

Overview

Pentachloropseudilin (PClP) is a chlorinated phenylpyrrole compound. It was first isolated from Actinoplanes (ATCC33002) Its structure has been confirmed by chemical synthesis.

ExcerptReferenceRelevance
"Pentachloropseudilin (PClP) is a reversible and allosteric inhibitor of type 1 myosin. "( Pentachloropseudilin Treatment Impairs Host Cell Invasion by Trypanosoma cruzi.
Borges, BC; da Silva, CV; de Gouveia Santos, J; de Oliveira, RC; Marques, IT; Spirandelli da Costa, M; Teixeira, TL, 2022)		3.61
"Pentachloropseudilin (PClP) is a chlorinated phenylpyrrole compound that was first isolated from Actinoplanes (ATCC33002), and its structure has been confirmed by chemical synthesis. "( Pentachloropseudilin Inhibits Transforming Growth Factor-β (TGF-β) Activity by Accelerating Cell-Surface Type II TGF-β Receptor Turnover in Target Cells.
Chen, CL; Chen, JJ; Chung, CL; Huang, YB; Kao, YC; Knölker, HJ; Lin, MH; Martin, R; Wang, SW; Wu, DC, 2018)		3.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Myosin-2 Heavy ChainDictyostelium discoideumIC50 (µMol)126.6000126.6000126.6000126.6000AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1693700Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 4 hrs by neutral red uptake assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID1693705Antimigratory activity against human MDA-MB-231 cells assessed as cell migration by light microscopy2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID1693698Antimigratory activity against human MDA-MB-231 cells assessed as cell migration at 2.5 uM by light microscopy relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID600882Inhibition of Dictyostelium discoideum myosin 2 motor domain-activated ATPase activity by spectrophotometry based PK/LDH coupled ATPase assay2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Inhibition of Myosin ATPase activity by halogenated pseudilins: a structure-activity study.
AID1693691Inhibition of rabbit skeletal muscle myosin-2 ATPase incubated for 20 mins followed by ATP addition and measured after 20 mins2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID1693699Antimigratory activity against human MDA-MB-231 cells assessed as minimum effective concentration by light microscopy2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID1693690Inhibition of rabbit muscle G-actin polymerization assessed as polymerized G-actin level at 25 uM incubated for 15 mins by spectrophotometric analysis (Rvb = 100 %)2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID600883Inhibition of Dictyostelium discoideum myosin 5b ATPase activity by spectrophotometric analysis2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Inhibition of Myosin ATPase activity by halogenated pseudilins: a structure-activity study.
AID600881Inhibition of Dictyostelium discoideum myosin 1b ATPase activity by spectrophotometric analysis2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Inhibition of Myosin ATPase activity by halogenated pseudilins: a structure-activity study.
AID1693704Cardiotoxicity in medaka embryo post hatching 24 hrs assessed as reduction in heart beat at 1.25 uM measured after 1 hr2021Bioorganic & medicinal chemistry, 01-15, Volume: 30In vitro and in vivo effects of inhibitors on actin and myosin.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2011The Journal of biological chemistry, Aug-26, Volume: 286, Issue:34
Mechanism and specificity of pentachloropseudilin-mediated inhibition of myosin motor activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (18.18)29.6817
2010's6 (54.55)24.3611
2020's3 (27.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.57 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.06 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pargyline
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.		2.0510aromatic amine
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		3.81100pyrrole;
secondary amine
silver
Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.		2.0510copper group element atom;
elemental silver		Escherichia coli metabolite
gallocatechol
(-)-epigallocatechin : A flavan-3,3',4',5,5',7-hexol having (2R,3R)-configuration.		2.3110catechin;
flavan-3,3',4',5,5',7-hexol		antioxidant;
food component;
plant metabolite
propargylamine
propargylamine: RN given refers to parent cpd; structure		2.0510
pentabromopseudilin
pentabromopseudilin: structure given in first source		3.0140pyrrolesmetabolite
blister
blebbistatin: structure in first source. blebbistatin : A pyrroloquinoline that is 1,2,3,3a-tetrahydro-H-pyrrolo[2,3-b]quinolin-4-one substituted by a hydroxy group at position 3a, a methyl group at position 6 and a phenyl group at position 1. It acts as an inhibitor of ATPase activity of non-muscle myosin II.		2.5320cyclic ketone;
pyrroloquinoline;
tertiary alcohol;
tertiary alpha-hydroxy ketone		inhibitor
quercetin
[no description available]		2.31107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
kaempferol
[no description available]		2.31107-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
blebbistatin
(S)-blebbistatin : The (S)-enantiomer of blebbistatin.		2.3110blebbistatin;
tertiary alpha-hydroxy ketone
cytochalasin b
Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.		2.3110cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		2.1710
ConditionIndicatedRelationship StrengthStudiesTrials